FORM 4

1. Name and Address of Reporting Person*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

> > 7. Nature of Indirect Beneficial Ownership (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

See footnotes⁽¹⁾
(2)(3)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						01 360	1)00 11011	1) 01 1	IIC IIIV	vesumen	Company	ACC 01 1340	'					
1. Name and Address of Reporting Person* RA CAPITAL MANAGEMENT, L.P.					2. Issuer Name and Ticker or Trading Symbol Acrivon Therapeutics, Inc. [ACRV]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					
(Last) 200 BEF	,	First) TREET, 18TH F	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 11/14/2022							Officer (give title Other (spe below) below)					
(Street) BOSTON MA 02116				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting						
(City) (State) (Zip)												Person						
		Т	able I - No	n-De	rivat	tive S	ecuriti	es A	Acqı	uired,	Dispose	d of, or	Benefi	cially	Owne	ed		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)			Execution Date		· 1	3. Transac Code (I 8)	ction Dispo	curities Acquired (A) sed Of (D) (Instr. 3, 4		or and 5)	Secu Bene Owne Repo	urities eficially ed Following orted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Natur Indirect Benefic Owners (Instr. 4				
										Code	V Amou		A) or D) P	rice	Trans	saction(s) r. 3 and 4)		<u> </u>
			Table II -								isposed s, conve				wned	i		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise or Exercise or Exercise Operivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)			action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y		ate	of Secur Underlyi	ng re Securit	Der Sec	rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature Indirect Beneficia Ownersh (Instr. 4)
					Code	v	(A)	(D)	Date Exer	e rcisable	Expiration Date	Title	Amour or Number of Shares	er				
Stock Option (Right to Buy)	\$12.5	11/14/2022			A		35,235			(2)	11/13/2032	Commor	35,23	5	\$0	35,235	I	See footn
		f Reporting Person												·			,	
(Last)	RKELEY S	(First) TREET, 18TH F	(Middl	e)														
(Street)	N	MA	02110	6														
(City)		(State)	(Zip)															
		f Reporting Person ³ lthcare Fund																
(Last) 200 BEF	RKELEY S	(First) TREET, 18TH F	(Middl	e)														
(Street)	N	MA	02110	6														
(City)		(State)	(Zip)															
		f Reporting Person us Fund II, L																
(Last) 200 BEF	RKELEY S	(First) TREET, 18TH F	(Middl	e)														
(Street)	N	MA	02110	6														
(City)		(State)	(Zip)															

(Last)	(First)	(Middle)
C/O RA CAPI	TAL MANAGEME	NT, L.P.
200 BERKELI	EY STREET, 18TH	FLOOR
(Street)		
BOSTON	MA	02116
(City)	(State)	(Zip)
	ress of Reporting Perso	n [*]
Shah Rajeev	<u>/ M.</u>	
Shah Rajeev (Last)	(First)	(Middle)
Shah Rajeev (Last) C/O RA CAPI	<u>/ M.</u>	(Middle)
Shah Rajeev (Last) C/O RA CAPI	(First)	(Middle)
Shah Rajeev (Last) C/O RA CAPI 200 BERKELI	(First)	(Middle)

Explanation of Responses:

- 1. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- 2. The shares subject to the option shall vest in 36 equal monthly installments starting on October 12, 2022 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to Dr. Derek DiRocco's continuous service through each such vesting date.
- 3. Dr. Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Remarks:

Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.

/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	11/16/2022
/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC the General Partner of RA Capital Healthcare Fund, L.P.	11/16/2022
/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund II GP, LLC the General Partner of RA Capital Nexus Fund II, L.P.	11/16/2022
/s/ Peter Kolchinsky, individually	11/16/2022
/s/ Rajeev Shah, individually	11/16/2022
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.